Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)
- PMID: 20451681
- DOI: 10.1016/j.amjcard.2009.12.059
Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)
Abstract
Acute myocardial infarction (AMI) initiates an intense inflammatory response in which interleukin-1 (IL-1) plays a central role. The IL-1 receptor antagonist is a naturally occurring antagonist, and anakinra is the recombinant form used to treat inflammatory diseases. The aim of the present pilot study was to test the safety and effects of IL-1 blockade with anakinra on left ventricular (LV) remodeling after AMI. Ten patients with ST-segment elevation AMI were randomized to either anakinra 100 mg/day subcutaneously for 14 days or placebo in a double-blind fashion. Two cardiac magnetic resonance (CMR) imaging and echocardiographic studies were performed during a 10- to 14-week period. The primary end point was the difference in the interval change in the LV end-systolic volume index (LVESVi) between the 2 groups on CMR imaging. The secondary end points included differences in the interval changes in the LV end-diastolic volume index, and C-reactive protein levels. A +2.0 ml/m(2) median increase (interquartile range +1.0, +11.5) in the LVESVi on CMR imaging was seen in the placebo group and a -3.2 ml/m(2) median decrease (interquartile range -4.5, -1.6) was seen in the anakinra group (p = 0.033). The median difference was 5.2 ml/m(2). On echocardiography, the median difference in the LVESVi change was 13.4 ml/m(2) (p = 0.006). Similar differences were observed in the LV end-diastolic volume index on CMR imaging (7.6 ml/m(2), p = 0.033) and echocardiography (9.4 ml/m(2), p = 0.008). The change in C-reactive protein levels between admission and 72 hours after admission correlated with the change in the LVESVi (R = +0.71, p = 0.022). In conclusion, in the present pilot study of patients with ST-segment elevation AMI, IL-1 blockade with anakinra was safe and favorably affected by LV remodeling. If confirmed in larger trials, IL-1 blockade might represent a novel therapeutic strategy to prevent heart failure after AMI.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].Am J Cardiol. 2013 May 15;111(10):1394-400. doi: 10.1016/j.amjcard.2013.01.287. Epub 2013 Feb 27. Am J Cardiol. 2013. PMID: 23453459 Free PMC article. Clinical Trial.
-
Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy.Am Heart J. 2009 Mar;157(3):541-7. doi: 10.1016/j.ahj.2008.11.011. Epub 2009 Jan 31. Am Heart J. 2009. PMID: 19249426 Clinical Trial.
-
Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study.Clin Cardiol. 2018 Aug;41(8):1004-1008. doi: 10.1002/clc.22988. Epub 2018 Aug 17. Clin Cardiol. 2018. PMID: 30033595 Free PMC article. Clinical Trial.
-
[Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].Ital Heart J. 2005 Nov;6 Suppl 7:14S-23S. Ital Heart J. 2005. PMID: 16485513 Review. Italian.
-
[Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease - case study and a review of literature].Vnitr Lek. 2012 Apr;58(4):313-8. Vnitr Lek. 2012. PMID: 22559807 Review. Czech.
Cited by
-
Fibroblasts in post-infarction inflammation and cardiac repair.Biochim Biophys Acta. 2013 Apr;1833(4):945-53. doi: 10.1016/j.bbamcr.2012.08.023. Epub 2012 Sep 7. Biochim Biophys Acta. 2013. PMID: 22982064 Free PMC article. Review.
-
IL-1β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy.J Clin Med. 2019 Oct 23;8(11):1764. doi: 10.3390/jcm8111764. J Clin Med. 2019. PMID: 31652822 Free PMC article. Review.
-
Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.Curr Atheroscler Rep. 2018 Sep 15;20(11):53. doi: 10.1007/s11883-018-0754-6. Curr Atheroscler Rep. 2018. PMID: 30219977 Review.
-
Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury.BMC Pharmacol Toxicol. 2020 Mar 12;21(1):21. doi: 10.1186/s40360-020-0400-0. BMC Pharmacol Toxicol. 2020. PMID: 32178737 Free PMC article.
-
Inflammation during Percutaneous Coronary Intervention-Prognostic Value, Mechanisms and Therapeutic Targets.Cells. 2021 Jun 4;10(6):1391. doi: 10.3390/cells10061391. Cells. 2021. PMID: 34199975 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials